Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Update

$Takeda Pharmaceutical(TAK.US)$ Takeda Says Primary And Key Secondary Endpoints Were Met In Narcolepsy Type 1 Phase 2b Trial;
The NT1 trial TAK-861-2001 evaluating TAK-861 in 112 patients demonstrated statistically significant and clinically meaningful improvement in objective and subjective measures of wakefulness compared to placebo at week 8 including on the primary endpoint Maintenance of Wakefulness Test (MWT) (p < 0.001).
Plans To Initiate Global Phase 3 Trials Of TAK-861 In Narcolepsy Type 1 Rapidly In H1 Of Its FY24
Takeda plans to initiate global Phase 3 trials of TAK-861 in NT1 rapidly in the first half of its fiscal year 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
2710 Views
Comment
Sign in to post a comment
    1673Followers
    28Following
    19KVisitors
    Follow